Despite the prominent role that EGFR plays in glioblastoma development and growth, therapeutic strategies targeted to the receptor have not been successful.45 Gefitinib was the second FDA-approved small molecule inhibitor and the first FDA-approved EGFR inhibitor, originally for treating non-small cell lung cancer patients harbouring EGFR mutations.196 In phase II clinical trials for newly diagnosed and recurrent glioblastoma patients, gefitinib offered no clinical benefit, with a median OS of 5–12 months.197–202. This evidence concerns the gene EGFR and glioblastoma.